Related Experiment Video
Updated: Apr 3, 2026
Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography
Published on: January 20, 2023
Immunologic monitoring during a phase 2a trial of the GNbAC1 antibody in patients with MS
Maria Zimmermann1, Nicholas S R Sanderson1, Maria Rasenack1
1Laboratory of Clinical Neuroimmunology (M.Z., N.S.R.S., M.R., R.L.P.L., L.K., T.D.), Department of Biomedicine, University Hospital Basel and University of Basel, Switzerland; Department of Neurology (M.R., L.K., T.D.), University Hospital Basel, Switzerland; Department of Neurosciences (P.H.L.), Division of Neurology, University Hospital Geneva and Faculty of Medicine, Geneva, Switzerland; and GeNeuro SA (A.B.L., F.C.), Plan-les-Ouates/Geneva, Switzerland.
Objective:
To monitor the systemic immune responses of patients with multiple sclerosis (MS) under treatment with GNbAC1, a monoclonal antibody against the envelope protein of the MS- associated retrovirus, during a phase 2a trial.
Methods:
We analyzed the composition of immune cell subsets and the activation level of monocytes by flow cytometry and the response against viral and vaccine antigens by ELISpot.
Results:
None of the endpoints measured revealed any immunosuppressive effect of the therapeutic antibody. Activation of monocytes slightly decreased during treatment as predicted by the hypothesized mechanism of action of GNbAC1.
Conclusion:
These results support the conclusion that the antibody is safe for use in patients with MS.
Classification Of Evidence:
This study provides Class III evidence that in patients with MS GNbAC1 does not significantly affect several biomarkers of systemic immune response.
More Related Videos
11:02Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
06:37Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
Published on: September 15, 2023